EMEA-002153-PIP01-17-M01 - paediatric investigation plan
fluticasone furoate
umeclidinium bromide
vilanterol trifenatate
PIPHuman
GlaxoSmithKline Trading Services Limited
Tel. +1 438-899-8201
E-mail: eu.paediatric-plans@gsk.com
P/0058/2020: EMA decision of 14 February 2020 on the refusal of a modification of an agreed paediatric investigation plan for fluticasone furoate / umeclidinium bromide / vilanterol trifenatate (Trelegy Ellipta / Elebrato Ellipta / Temybric Ellipta)